Myriad Genetics Invests $25M in Crescendo Bio with Option to Acquire | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday that it has made a $25 million debt investment into Crescendo Bioscience and secured a three-year option to purchase the developer of molecular diagnostics targeting autoimmune diseases.

Separate from Myriad's investment, Crescendo said that it had completed its $31 million in Series C equity financing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.